These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37542281)

  • 21. Optimization of prophylaxis for hemophilia A.
    Herbert RD; Broderick CR; Barnes C; Billot L; Zhou A; Latimer J
    PLoS One; 2018; 13(2):e0192783. PubMed ID: 29447219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study.
    Stasyshyn O; Antunes S; Mamonov V; Ye X; Epstein J; Xiong Y; Tangada S
    Haemophilia; 2014 Sep; 20(5):644-50. PubMed ID: 24589084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The benefit of low dose prophylaxis in the treatment of hemophilia: a focus on China.
    Wu R; Luke KH
    Expert Rev Hematol; 2017 Nov; 10(11):995-1004. PubMed ID: 28971697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Stobart K; Iorio A; Wu JK
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003429. PubMed ID: 15846666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.
    Tagliaferri A; Feola G; Molinari AC; Santoro C; Rivolta GF; Cultrera DB; Gagliano F; Zanon E; Mancuso ME; Valdré L; Mameli L; Amoresano S; Mathew P; Coppola A;
    Thromb Haemost; 2015 Jul; 114(1):35-45. PubMed ID: 25855376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term analysis of the benefit of prophylaxis for adult patients with severe or moderate haemophilia A.
    Miesbach W; Kittler S; Bauhofer A; Königs C; Becker T; Nemes L; Staus A; Schüttrumpf J
    Haemophilia; 2020 May; 26(3):467-477. PubMed ID: 32293085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review.
    Sun J; Zhou X; Hu N
    Orphanet J Rare Dis; 2021 Jun; 16(1):287. PubMed ID: 34174912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.
    Iorio A; Marchesini E; Marcucci M; Stobart K; Chan AK
    Cochrane Database Syst Rev; 2011 Sep; (9):CD003429. PubMed ID: 21901684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.
    Ragni MV
    Expert Rev Hematol; 2011 Oct; 4(5):495-507. PubMed ID: 21939418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study.
    Gringeri A; Leissinger C; Cortesi PA; Jo H; Fusco F; Riva S; Antmen B; Berntorp E; Biasoli C; Carpenter S; Kavakli K; Morfini M; Négrier C; Rocino A; Schramm W; Windyga J; Zülfikar B; Mantovani LG
    Haemophilia; 2013 Sep; 19(5):736-43. PubMed ID: 23731246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of medical insurance schemes and charity assistance projects on regular prophylaxis treatment of the boys with severe haemophilia A in China.
    Li Z; Wu J; Zhao Y; Liu R; Li K; Zhou Y; Wu R; Yang R; Zhang X; Lian S; Hu Q; Li X; Gu J; Zhou R; Sun J; Li C; Xu W; Poon MC; Xiao J
    Haemophilia; 2018 Jan; 24(1):126-133. PubMed ID: 29148258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A cost-effectiveness analysis of the prophylaxis versus on-demand regimens in severe hemophilia A patients under 12 years old in southern Iran.
    Zahedi Z; Karimi M; Keshavarz K; Haghpanah S; Ravangard R
    Hematology; 2021 Dec; 26(1):240-248. PubMed ID: 33594948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A.
    Fischer K; Pouw ME; Lewandowski D; Janssen MP; van den Berg HM; van Hout BA
    Haematologica; 2011 May; 96(5):738-43. PubMed ID: 21273268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial.
    Stasyshyn O; Djambas Khayat C; Iosava G; Ong J; Abdul Karim F; Fischer K; Veldman A; Blackman N; St Ledger K; Pabinger I
    J Thromb Haemost; 2017 Apr; 15(4):636-644. PubMed ID: 28166608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of short-term full-dose prophylaxis in adult Chinese patients with severe hemophilia A].
    Sun X; Zhuang J; Zhou X; Li H; Liu Z; Sun J
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Sep; 38(10):1222-1227. PubMed ID: 30377129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iranian Low-dose Escalating Prophylaxis Regimen in Children with Severe Hemophilia A and B.
    Eshghi P; Sadeghi E; Tara SZ; Habibpanah B; Hantooshzadeh R
    Clin Appl Thromb Hemost; 2018 Apr; 24(3):513-518. PubMed ID: 28049359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.
    Skinner MW; Négrier C; Paz-Priel I; Chebon S; Jiménez-Yuste V; Callaghan MU; Lehle M; Niggli M; Mahlangu J; Shapiro A; Shima M; Campinha-Bacote A; Levy GG; Oldenburg J; von Mackensen S; Pipe SW
    Haemophilia; 2021 Sep; 27(5):854-865. PubMed ID: 34171159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1.
    O'Mahony B; Dunn AL; Leavitt AD; Peyvandi F; Ozelo MC; Mahlangu J; Peerlinck K; Wang JD; Lowe GC; Tan CW; Giermasz A; Tran H; Khoo TL; Cockrell E; Pepperell D; Chambost H; López Fernández MF; Kazmi R; Majerus E; Skinner MW; Klamroth R; Quinn J; Yu H; Wong WY; Robinson TM; Pipe SW
    J Thromb Haemost; 2023 Dec; 21(12):3450-3462. PubMed ID: 37678546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors.
    Hoots WK; Ebbesen LS; Konkle BA; Auerswald GK; Roberts HR; Weatherall J; Ferran JM; Ljung RC;
    Haemophilia; 2008 May; 14(3):466-75. PubMed ID: 18282155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of prophylaxis on health-related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries.
    Usuba K; Price VE; Blanchette V; Abad A; Altisent C; Buchner-Daley L; Carneiro JDA; Feldman BM; Fischer K; Grainger J; Holzhauer S; Luke KH; Meunier S; Ozelo M; Tang L; Antunes SV; Villaça P; Wakefield C; Wharfe G; Wu R; Young NL
    Res Pract Thromb Haemost; 2019 Jul; 3(3):397-404. PubMed ID: 31294327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.